Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study

Norquist Barbara M.; Brady Mark F.; Harrell Maria I.; Walsh Tom; Lee Ming K.; Gulsuner Suleyman; Bernards Sarah S.; Casadei Silvia; Burger Robert A.; Tewari Krishnansu S.; Backes Floor; Mannel Robert S.; Glaser Gretchen; Bailey Cheryl; Rubin Stephen; Soper John; Lankes Heather A.; Ramirez Nilsa C.; King Mary Claire; Birrer Michael J.; Swisher Elizabeth M.

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study

【24h】

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study

机译：GOG 218中卵巢癌患者在同源重组基因和结果中的突变：NRG肿瘤学/妇科肿瘤学群体研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: We hypothesized that mutations in homologous recombination repair (HRR) genes beyond BRCA1 and BRCA2 improve outcomes for ovarian carcinoma patients treated with platinum therapy and would impact the relative benefit of adding prolonged bevacizumab.

机译：目的：我们假设在BRCA1和BRCA2之外的同源重组修复（HRR）基因中的突变改善了用铂治疗治疗的卵巢癌患者的结果，并影响增加延长贝伐单抗的相对益处。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2018年第4期|共7页
作者
Norquist Barbara M.; Brady Mark F.; Harrell Maria I.; Walsh Tom; Lee Ming K.; Gulsuner Suleyman; Bernards Sarah S.; Casadei Silvia; Burger Robert A.; Tewari Krishnansu S.; Backes Floor; Mannel Robert S.; Glaser Gretchen; Bailey Cheryl; Rubin Stephen; Soper John; Lankes Heather A.; Ramirez Nilsa C.; King Mary Claire; Birrer Michael J.; Swisher Elizabeth M.;
展开▼
作者单位

Univ Washington Div Gynecol Oncol Seattle WA 98195 USA;

Roswell Pk Canc Ctr Inst NRG Oncol Stat &

Data Ctr Buffalo NY USA;

Univ Washington Div Gynecol Oncol Seattle WA 98195 USA;

Univ Washington Dept Med Div Med Genet Seattle WA 98195 USA;

Univ Washington Dept Med Div Med Genet Seattle WA 98195 USA;

Univ Washington Dept Med Div Med Genet Seattle WA 98195 USA;

Univ Washington Div Gynecol Oncol Seattle WA 98195 USA;

Univ Washington Dept Med Div Med Genet Seattle WA 98195 USA;

Univ Penn Div Gynecol Oncol Philadelphia PA 19104 USA;

Univ Calif Irvine Div Gynecol Oncol Orange CA 92668 USA;

Ohio State Univ Med Ctr Div Gynecol Oncol Columbus OH 43210 USA;

Univ Oklahoma Div Gynecol Oncol Oklahoma City OK USA;

Mayo Clin Div Gynecol Surg Rochester MN USA;

Minnesota Oncol Div Gynecol Oncol Minneapolis MN USA;

Fox Chase Canc Ctr Dept Surg Oncol Div Gynecol Oncol 7701 Burholme Ave Philadelphia PA 19111;

Univ N Carolina Div Gynecol Oncol Chapel Hill NC USA;

Nationwide Childrens Hosp Res Inst Dept Pathol &

Lab Med Columbus OH USA;

Nationwide Childrens Hosp Res Inst Dept Pathol &

Lab Med Columbus OH USA;

Univ Washington Dept Med Div Med Genet Seattle WA 98195 USA;

Univ Alabama Birmingham Div Hematol Oncol Birmingham AL 35294 USA;

Univ Washington Div Gynecol Oncol Seattle WA 98195 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study [J] . Norquist Barbara M., Brady Mark F., Harrell Maria I., Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第4期

机译：GOG 218中卵巢癌患者在同源重组基因和结果中的突变：NRG肿瘤学/妇科肿瘤学群体研究
2. Risk Factors for Readmission in Patients With Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Who Are Receiving Front-line Chemotherapy on a Clinical Trial (GOG 218): An NRG Oncology/Gynecologic Oncology Group Study (ADS-1236) EDITORIAL COMMENT [J] . Van Le Linda Obstetrical and gynecological survey . 2016,第1期

机译：在临床试验中接受一线化疗的卵巢癌，输卵管癌和原发性腹膜癌患者再次入院的危险因素（GOG 218）：NRG肿瘤/妇科肿瘤学组研究（ADS-1236）编辑评论
3. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236) [J] . Duska Linda R., Java James J., Cohn David E., Gynecologic Oncology: An International Journal . 2015,第2期

机译：在临床试验中接受一线化疗的卵巢癌，输卵管癌和原发性腹膜癌患者再次入院的危险因素（GOG 218）：NRG肿瘤/妇科肿瘤组研究（ADS-1236）
4. Sodium selenite in gynecologic radiation oncology. Results of a phase III study [C] . Muecke, R., Glatzel, Workshop on Macro, Trace and Ultratrace Elements; 20040924-25; Jena(DE) . 2004

机译：亚硒酸钠在妇科放射肿瘤学中的应用。第三阶段研究的结果
5. Ensemble Learning for Predicting Gynecological Oncology Patients Using Travel Distance [D] . Jarett, Jamie. 2019

机译：用于预测使用旅行距离预测妇科肿瘤患者的合奏学习
6. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study [O] . Barbara M. Norquist, Mark F. Brady, Maria I. Harrell, -1

机译：GOG 218中卵巢癌患者同源重组基因的突变和结果：NRG肿瘤/妇科肿瘤小组研究
7. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254) [O] . John K. Chan, William Brady, Bradley J. Monk, 2018

机译：Sunitinib在治疗持续或复发性透明细胞卵巢癌中的II期评价：NRG肿瘤学/妇科肿瘤学群体研究（GOG-254）

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study

摘要

著录项

相似文献

相关主题

期刊订阅